This content is from: Home

Revealed: university patent transaction trends 2013

Universities develop plenty of IP, and are increasingly good at commercialising it. But which universities are most active when it comes to developing and transferring their rights? Rubal Walia of INDUS TechInnovations explains

Universities play a crucial role in advancing technologies through their research activities. Consequently, the process of technology transfer and commercialisation of IP by universities has gained significance. To gain insights into the patterns and trends, we studied the university transactions recorded by the USPTO during 2013.

In this infographic, we have outlined some interesting trends such as top transacted technologies, university rankings, and filing trends over the years. In addition, data points from 2012 provide a notable comparison of how the universities stack up as compared to the previous year. For a detailed analysis, we have segregated the report into two major chunks, studying transactions to government agencies and corporate entities respectively.

From the university-related transactions that occurred in 2013, technologies in healthcare, medical imaging and diagnostics, and semiconductors (to some extent) dominated. Notable changes between 2012 and 2013 include Rochester University’s emergence as one of the top three assignors last year (it had been involved in just 20 assignments in 2012) and Sloan Keating Cancer Centre’s move down the list, assigning a mere 22 patent transactions during 2013.

The report also indicates that universities based in Asian countries such Japan, Korea and Taiwan have carried out a good amount of patent transactions. Here’s a detailed look at how universities have fared in IP commercialisation activities last year.

Click on image to enlarge

The infographic was produced by Relecura, a patent and portfolio analysis platform developed by INDUS TechInnovations.

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.


Instant access to all of our content. Membership Options | 30 Day Trial